Zai Lab Shares Climb Over 4% Following Global Clinical Partnership with Amgen for Small Cell Lung Cancer Treatment

Stock News09:52

Zai Lab (09688) rose more than 4% in Hong Kong trading, with the stock up 4.22% to HK$15.79 by the time of writing, as turnover reached HK$98.01 million. The increase follows an announcement on April 1 that Zai Lab has entered into a global clinical research collaboration with Amgen. The partnership aims to evaluate Zai Lab’s clinical-stage antibody-drug conjugate (ADC) zocilurtatug pelitecan (zoci, formerly known as ZL-1310), which targets delta-like ligand 3 (DLL3), in combination with Amgen’s IMDELLTRA® (tarlatamab), a bispecific T-cell engager (BiTE®) therapy also targeting DLL3, for the treatment of patients with extensive-stage small cell lung cancer (ES-SCLC). Under the agreement, Amgen will sponsor a global Phase 1b study to assess the safety and efficacy of zoci combined with IMDELLTRA® in ES-SCLC patients. Zai Lab will retain full ownership of zoci and will supply the investigational drug for the clinical study.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment